Schistosoma japonicum Tetraspanin-2 Vaccine Study
Author Information
Author(s): Zhang Wenbao, Li Jun, Duke Mary, Jones Malcolm K., Kuang Ling, Zhang Jianfeng, Blair David, Li Yuesheng, McManus Donald P.
Primary Institution: Queensland Institute of Medical Research, Brisbane, Queensland, Australia
Hypothesis
Can Schistosoma japonicum Tetraspanin-2 (Sj-TSP-2) serve as an effective vaccine target?
Conclusion
The highly polymorphic nature of the Sj-TSP-2 gene limits its value as a target for future S. japonicum vaccine development.
Supporting Evidence
- Vaccination of mice with the recombinant protein induced high levels of IgG1 and IgG2 antibodies.
- 43.1% of sera from confirmed schistosomiasis japonica patients recognized the purified recombinant protein.
- The study identified 7 different clusters of S. japonicum TSP-2 based on sequence variation.
Takeaway
Researchers tried to use a part of a parasite to make a vaccine, but it didn't work well because the parasite changes a lot.
Methodology
The study involved cloning, sequencing, and expressing the Sj-TSP-2 protein, followed by vaccination trials in mice and analysis of immune responses.
Limitations
The study faced challenges in achieving consistent protective efficacy across trials.
Participant Demographics
Human sera collected from confirmed schistosomiasis japonica cases in Hunan province, China.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website